Abstract
AbstractProline-rich antimicrobial peptides (PrAMPs) inhibit bacterial protein biosynthesis by binding to the polypeptide exit tunnel (PET) near the peptidyl transferase center. Api137, an optimized derivative of honeybee PrAMP apidaecin, inhibits protein expression by trapping release factors (RFs), which interact with stop codons on ribosomes to terminate translation. This study uses cryo-EM, functional assays and molecular dynamic (MD) simulations to show that Api137 additionally occupies a second binding site near the exit of the PET and can repress translation independently of RF-trapping. Api88, a C-terminally amidated (-CONH2) analog of Api137 (-COOH), binds to the same sites, occupies a third binding pocket and interferes with the translation process presumably without RF-trapping. In conclusion, apidaecin-derived PrAMPs inhibit bacterial ribosomes by multimodal mechanisms caused by minor structural changes and thus represent a promising pool for drug development efforts.
Funder
Bundesministerium für Bildung und Forschung
German Federal Ministry for Education and Research
Publisher
Springer Science and Business Media LLC
Reference68 articles.
1. D’Costa, V. et al. Antibiotic resistance is ancient. Nature 477, 457–461 (2011).
2. O’Neill, J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev. Antimicrob. Resist., (2014).
3. Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).
4. Dini, I., Biasi, M. De, Antibiotics, A. M.-& 2022, undefined. An overview of the potentialities of antimicrobial peptides derived from natural sources. Antibiotics 11, 1483 (2022).
5. Graf, M. & Wilson, D. N. Intracellular antimicrobial peptides targeting the protein synthesis machinery. Adv. Exp. Med Biol. 1117, 73–89 (2019).